Approval · Notice of Compliance 32616 · 2024
OLUMIANT: Notice of Compliance 32616
Issued January 26, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32616
- Date
- January 26, 2024
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for alopecia areata. Addition of a 4 mg tablet strength.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OLUMIANT | Not yet assigned | — |
| OLUMIANT | 02544768 | Marketed |
Medicinal ingredients
- BARICITINIB 2 MG per TAB
- BARICITINIB 4 MG per TAB